Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

Diabetes. 2011 Apr;60(4):1246-57. doi: 10.2337/db10-1338. Epub 2011 Feb 17.

Abstract

Objective: Diet composition alters the metabolic states of adipocytes and hepatocytes in diabetes. The effects of dipeptidyl peptidase-4 (DPP-4) inhibition on adipose tissue inflammation and fatty liver have been obscure. We investigated the extrapancreatic effects of DPP-4 inhibition on visceral fat and the liver.

Research design and methods: We investigated diet-induced metabolic changes in β-cell-specific glucokinase haploinsufficient (Gck(+/-)) diabetic mice. We challenged animals with a diet containing a combination of sucrose and oleic acid (SO) or sucrose and linoleic acid (SL). Next, we assessed the effects of a DPP-4 inhibitor, des-fluoro-sitagliptin, on adipose tissue inflammation and hepatic steatosis.

Results: The epididymal fat weight and serum leptin level were significantly higher in Gck(+/-) mice fed SL than in mice fed SO, although no significant differences in body weight or adipocyte size were noted. Compared with SO, SL increased the numbers of CD11c(+) M1 macrophages and CD8(+) T-cells in visceral adipose tissue and the expression of E-selectin, P-selectin, and plasminogen activator inhibitor-1 (PAI-1). DPP-4 inhibition significantly prevented adipose tissue infiltration by CD8(+) T-cells and M1 macrophages and decreased the expression of PAI-1. The production of cytokines by activated T-cells was not affected by DPP-4 inhibition. Furthermore, DPP-4 inhibition prevented fatty liver in both wild-type and Gck(+/-) mice. DPP-4 inhibition also decreased the expressions of sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase-1, and fatty acid synthase, and increased the expression of peroxisome proliferator-activated receptor-α in the liver.

Conclusions: Our findings indicated that DPP-4 inhibition has extrapancreatic protective effects against diet-induced adipose tissue inflammation and hepatic steatosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects
  • Adipose Tissue / immunology*
  • Adipose Tissue / pathology*
  • Animals
  • Blood Glucose / drug effects
  • Body Weight / drug effects
  • Chemokine CCL2 / metabolism
  • Dietary Fats / adverse effects*
  • Dietary Sucrose / adverse effects*
  • Dipeptidyl Peptidase 4 / genetics
  • Dipeptidyl Peptidase 4 / metabolism*
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology*
  • Enzyme-Linked Immunosorbent Assay
  • Exenatide
  • Fatty Liver / metabolism
  • Fatty Liver / prevention & control*
  • Female
  • Glucokinase / genetics
  • Glucokinase / metabolism
  • Hypertrophy / chemically induced
  • Insulin / blood*
  • Interferon-gamma / metabolism
  • Interleukin-10 / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mice
  • Peptides / pharmacology
  • Polymerase Chain Reaction
  • Triglycerides / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Venoms / pharmacology

Substances

  • Blood Glucose
  • Chemokine CCL2
  • Dietary Fats
  • Dietary Sucrose
  • Dipeptidyl-Peptidase IV Inhibitors
  • Insulin
  • Peptides
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • Venoms
  • Interleukin-10
  • Interferon-gamma
  • Exenatide
  • Glucokinase
  • Dipeptidyl Peptidase 4